NanoViricides' NV-387 Emerges as Potential Breakthrough in Measles Treatment Amid Global Outbreaks

NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of broad-spectrum antiviral therapies, has spotlighted its drug candidate NV-387 as a potential game-changer in the fight against measles, a disease witnessing alarming resurgence globally. With measles cases in the U.S. hitting a record 1,319 in 2025 and Canada reporting over 3,800 cases, the urgency for effective treatments has never been more pronounced. The World Health Organization's report of 127,350 cases in Europe in 2024, the highest since 1997, further underscores the critical need for innovative solutions.

NV-387, developed using NanoViricides' proprietary host-mimetic nanomedicine technology, has demonstrated promising results in animal studies and completed a Phase I clinical trial with no adverse events, signaling its safety and tolerability in humans. The company believes NV-387 could qualify for Orphan Drug and Fast Track designations, which would not only expedite its approval process but also grant seven years of market exclusivity, a significant advantage in addressing this unmet medical need.

The absence of an approved drug for measles, compounded by challenges in vaccination rates due to hesitancy and immune dysfunction, positions NV-387 as a pivotal development in public health. NanoViricides' approach to leveraging nanomedicine technology offers a novel pathway to combat not only measles but also other viral infections, including RSV, COVID-19, and influenza, marking a significant stride forward in antiviral therapy.

For further details on NanoViricides' groundbreaking work and the potential of NV-387, visit https://ibn.fm/w2BR6. Additional information about the company and its innovative technologies can be found at https://www.NanoViricides.com.